Author + information
- Received May 23, 2015
- Revision received July 20, 2015
- Accepted July 21, 2015
- Published online September 29, 2015.
- Jeffrey J. Goldberger, MD, MBA∗∗ (, )
- Robert O. Bonow, MD∗,
- Michael Cuffe, MD†,
- Lei Liu, PhD‡,
- Yves Rosenberg, MD, MPH§,
- Prediman K. Shah, MD‖,
- Sidney C. Smith Jr., MD¶,
- Haris Subačius, MA∗,
- OBTAIN Investigators
- ∗Center for Cardiovascular Innovation and the Division of Cardiology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois
- †Hospital Corporation of America, Brentwood, Tennessee
- ‡Department of Preventive Medicine, Northwestern University, Chicago, Illinois
- §Division of Cardiovascular Sciences, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland
- ‖Cedars-Sinai Heart Institute, Cedars-Sinai Medical Center, Los Angeles, California
- ¶Heart and Vascular Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina
- ↵∗Reprint requests and correspondence:
Dr. Jeffrey J. Goldberger, Northwestern University Feinberg School of Medicine, Division of Cardiology, 676 North Saint Clair, Arkes 600, Chicago, Illinois 60611.
Background Beta-blocker therapy after acute myocardial infarction (MI) improves survival. Beta-blocker doses used in clinical practice are often substantially lower than those used in the randomized trials establishing their efficacy.
Objectives This study evaluated the association of beta-blocker dose with survival after acute MI, hypothesizing that higher dose beta-blocker therapy will be associated with increased survival.
Methods A multicenter registry enrolled 7,057 consecutive patients with acute MI. Discharge beta-blocker dose was indexed to the target beta-blocker doses used in randomized clinical trials, grouped as >0% to 12.5%, >12.5% to 25%, >25% to 50%, and >50% of target dose. Follow-up vital status was assessed, with the primary endpoint of time-to-death right-censored at 2 years. Multivariable and propensity score analyses were used to account for group differences.
Results Of 6,682 patients with follow-up (median 2.1 years), 91.5% were discharged on a beta-blocker (mean dose 38.1% of the target dose). Lower mortality was observed with all beta-blocker doses (p < 0.0002) versus no beta-blocker therapy. After multivariable adjustment, hazard ratios for 2-year mortality compared with the >50% dose were 0.862 (95% confidence interval [CI]: 0.677 to 1.098), 0.799 (95% CI: 0.635 to 1.005), and 0.963 (95% CI: 0.765 to 1.213) for the >0% to 12.5%, >12.5% to 25%, and >25% to 50% of target dose groups, respectively. Multivariable analysis with an extended set of covariates and propensity score analysis also demonstrated that higher doses were not associated with better outcome.
Conclusions These data do not demonstrate increased survival in patients treated with beta-blocker doses approximating those used in previous randomized clinical trials compared with lower doses. These findings provide the rationale to re-engage in research to establish appropriate beta-blocker dosing after MI to derive optimal benefit from this therapy. (The PACE-MI Registry Study—Outcomes of Beta-blocker Therapy After Myocardial Infarction [OBTAIN]: NCT00430612)
Beta-blocker therapy after myocardial infarction (MI) improves survival. On the basis of randomized clinical trials (1,2) and large observational studies (3–5), guidelines for the management of patients after ST-segment elevation MI (6) and non–ST-segment elevation MI (7) recommend beta-blocker therapy in essentially all post-MI patients without contraindications. The randomized clinical trials did not assess the effects of different doses of beta-blockers, and there have been no large-scale studies that have addressed this topic. Although the guidelines do not refer to specific beta-blockers or doses, basic evidence-based medicine principles support the use of beta-blockers that have been studied in trials at the doses used or targeted; trials that report dosing indicate that the majority of patients achieved target doses. However, doses of clinically used beta-blocker are substantially lower (8,9). The impact of this large-scale underdosing of beta-blockers on the beneficial effects of beta-blocker therapy is unknown. Analyses of post-MI beta-blocker trials have related mortality reduction to heart rate reduction (10,11); because heart rate reduction is dose dependent, this supports the notion that there could be a dose-dependent reduction in mortality. The OBTAIN (Outcomes of Beta-blocker Therapy After Myocardial Infarction) study is an observational multicenter registry in which beta-blocker dosing information was collected in all patients with acute MI at participating centers to assess the effect of dose on survival. The OBTAIN hypothesis was that higher dose beta-blocker therapy is associated with increased survival.
Study design and oversight
Initiated in 2007, OBTAIN was a companion registry to the PACE-MI (PACEmaker and ß-Blocker Therapy Post-Myocardial Infarction) trial (12). Detailed information on beta-blocker dosing was collected in the registry. There were 26 participating centers in the United States and 1 in Canada. When the trial was terminated in 2009, it was noted that beta-blocker utilization was nearly universal, but that most patients were treated with doses ≤25% of the target doses used in clinical trials. At that time, the decision was made to continue the registry and evaluate vital status for at least 2 years to test the hypothesis that there is a dose–response relationship in the beneficial effect of beta-blocker therapy on survival. After protocol modification to include vital status assessment and resubmission for institutional review board approval, 21 of the original sites continued their participation (including 92% of the registry patients). An additional 5 U.S. sites were recruited.
The study was funded by the National Heart, Lung, and Blood Institute, and an observational study monitoring board, appointed by the institute, monitored study conduct. The study was approved by each site’s institutional review board with a waiver of consent for registry enrollment. Participating centers and study committees and personnel are listed in the Online Appendix.
Consecutive patients admitted with acute MI at participating sites were entered into the registry. Acute MI was diagnosed by: 1) either creatine kinase elevation >2 times or troponin elevation >3 times the upper limit of normal; and 2) either chest pain (or equivalent symptoms suggestive of MI) or electrocardiographic changes consistent with MI.
Basic demographic, historical, and hospitalization information, as well as information regarding the index MI, was collected. Discharge beta-blocker type and dose were recorded. All data were collected at the site, and deidentified patient information was entered in a Web-based electronic data capture system.
Beta-blocker type and dose were chosen by the managing physician. For the purposes of the present study, target doses for the most commonly used beta-blockers were as follows: metoprolol 200 mg/day (13,14); carvedilol 50 mg/day (15) (Coreg CR [GlaxoSmithKline Pharmaceuticals, Philadelphia, Pennsylvania]–equivalent dose 80 mg/day); propranolol 180 mg/day (16); timolol 20 mg/day (17); bisoprolol 10 mg/day (18); and atenolol 100 mg/day (19). On the basis of the dose administered, a proportion of the target dose was calculated (administered/target dose) only for patients taking 1 of these beta-blockers. Beta-blocker doses were divided into 5 pre-specified groups: no beta-blocker, >0% to 12.5%, >12.5% to 25%, >25% to 50%, and >50% of the target dose.
The pre-specified endpoint for this study was time to all-cause mortality with survival right-censored at 2 years. Vital status was assessed by use of chart review, the Social Security Administration’s Death Master File, or direct communication with the patient/family. Per protocol, vital status was assessed 1 and 2 years after MI. Follow-up using the Social Security Administration’s Death Master File incorporated a 6-month delay to account for the lag time in recording deaths. A longer term follow-up (>3 years) was available, particularly for sites that participated in the original registry.
Patient characteristics were summarized as mean ± SD or count (%). Differences among groups were compared by using chi-square tests for categorical variables and analysis of variance for continuous variables. Distribution-free rank sum tests were used for variables that deviated from normality. The median (interquartile range) was used to summarize these variables. The Kaplan-Meier method was used to calculate 1-, 2-, and 3-year survival in each study group.
Pre-specified analysis of the effect of the 5 pre-specified groups on 2-year survival was tested by comparing Kaplan-Meier survival curves with a log-rank test. Cox proportional hazards regression was used to test for the independent effects of beta-blocker dosing on survival. The following pre-specified patient characteristics were used in multivariable adjustment: age, sex, white race, Hispanic ethnicity, cardiac enzymes, left ventricular ejection fraction, diabetes, hypertension, hypercholesterolemia, ST-segment elevation MI, thrombolytic therapy, primary percutaneous coronary intervention, length of stay, and other discharge medications (aspirin, angiotensin-converting enzyme [ACE] inhibitors/angiotensin receptor blockers, and statins). A pre-specified secondary analysis was performed comparing the outcomes for low-dose (≤25%) and high-dose (≥50%) beta-blocker therapy.
Further sensitivity analyses of the effect of the 4 beta-blocker doses on outcome included evaluation of 3-year outcomes. Multivariable analysis included an expanded set of all covariates listed in Table 1, including use of carvedilol versus metoprolol. Random effects (shared frailty model) were also included for each of the recruiting hospitals to better model differences in mortality among them. Quadratic and cubic polynomial terms for continuous predictors were included to account for potential nonlinearity.
Propensity score analysis was also performed as an alternative adjustment for patient differences in the 4 beta-blocker dose groups. To calculate the propensity score, we used mixed effects linear regression with random effects of the recruiting centers, continuous discharge beta-blocker dose (percentage of target dose) as a dependent variable, and the expanded control variable set reported in Table 1 (including quadratic and cubic polynomial terms for continuous predictors). Thus, the propensity scores represent the predicted discharge beta-blocker dose, given the extended set of patient characteristics. The propensity score was used as a control variable in the proportional hazards frailty regression model. Further details are provided in the Online Appendix.
All tests were 2-tailed, and a conventional 5% significance level was used. A gatekeeper hypothesis strategy for type I error control was used for pre-specified study endpoints; alpha levels were to be adjusted for subsequent tests if the gatekeeper null hypothesis was rejected. Analyses were performed by using SAS version 9.4 (SAS Institute, Inc., Cary, North Carolina).
The registry included 7,057 patients. In-hospital mortality was 4.7%, and 43 patients were lost to follow-up. Table 1 displays baseline characteristics of the 6,682 patients discharged alive, stratified according to beta-blocker use. The mean age across groups was 63 to 65 years, with male predominance. Small to moderate group differences were noted for most characteristics.
Discharge therapy included beta-blockers (91.5%), aspirin (92.6%), ACE inhibitors/angiotensin receptor blockers (66.3%), and statins (86.3%). There were 567 patients (8.5%) discharged without beta-blocker therapy. Reasons provided for not administering beta-blockers included low blood pressure (26%), conduction system disease (16%), pulmonary disease (17%), heart failure (9%), drug use (5%), debilitation (5%), and other (22%).
Beta-blockers administered at discharge included metoprolol (67.7%), carvedilol (24.3%), atenolol (3.8%), bisoprolol (2.8%), propranolol (0.2%), and others (1.1%). Of the patients discharged on a beta-blocker, 24.0%, 37.2%, 25.5%, and 13.4% received >0% to 12.5%, >12.5% to 25%, >25% to 50%, and >50% of the target dose, respectively. The mean administered dose was 38.1% of the target dose. Median follow-up was 2.1 years (interquartile range: 2.0 to 2.5 years). At last follow-up (n = 3,581), 52.4%, 20.2%, and 20.2% were taking the same, a higher, or a lower dose, respectively, with a 3.8% discontinuation rate and a 3.4% initiation rate in patients not discharged on beta-blockers. From discharge to 1 year, of the patients treated with >12.5% to 25% of the target dose, only 4% were subsequently in the >50% of the target dose group. Of the patients treated with >50% of the target dose, only 12% were subsequently treated with ≤25% of the target dose. In this cohort, beta-blocker therapy was associated with an unadjusted 51% (adjusted 45%; 95% confidence interval [CI]: 33% to 55%) lower mortality compared with no beta-blocker therapy.
At 2 years, there were a total of 831 deaths (post-discharge mortality of 12.4%). The Central Illustration (panel A) displays the Kaplan-Meier curves for the primary analysis. Tables 2 and 3 provide the hazard ratios (HRs) relative to no beta-blocker use and to the >50% target dose. Multivariable analysis identified that all tested parameters were independently related to survival (Table 4). After the pre-specified multivariable adjustment, relative to the >50% target dose, mortality did not differ for the >0% to 12.5% and >25% to 50% doses, and was borderline statistically significant in those taking >12.5% to 25% of the target dose but not after multivariable adjustment with the extended set of covariates.
The Kaplan-Meier curves for low-dose (≤25%) versus high-dose (≥50%) beta-blocker therapy (Central Illustration, panel B) show a significantly lower mortality with low-dose therapy compared with high-dose therapy (HR: 0.758; 95% CI: 0.651 to 0.883; p = 0.0004). After multivariable adjustment (Table 4), there was lower mortality (HR: 0.857; 95% CI: 0.734 to 1.002; p = 0.05) with low- versus high-dose therapy but not after multivariable adjustment with the extended set of covariates (Table 2).
Table 3 presents the multivariable HRs with extended follow-up to 3 years (using the pre-specified multivariable analysis) and the analyses focusing on the 4 beta-blocker dose groups using multivariable analysis with the expanded set of covariates (Table 5) and the propensity score analysis. Relative to the >50% dose group, there were no significant differences between the >0% to 12.5% and >25% to 50% dose groups. Although there were lower HRs in the >12.5% to 25% dose group, these findings were not consistently significant across all analyses. Because the >12.5% to 25% group was the largest and experienced the lowest mortality, the HRs relative to the >12.5% to 25% dose group were analyzed (Figure 1). Increased HRs were noted in the >0% to 12.5% dose group (expanded multivariable HR: 1.092; 95% CI: 0.896 to 1.331; p = 0.38; propensity score HR: 1.394; 95% CI: 1.148 to 1.692; p = 0.0008) and the >25% to 50% dose group (expanded multivariable HR: 1.176; 95% CI: 0.973 to 1.420; p = 0.09; propensity score HR: 1.248; 95% CI: 1.035 to 1.505; p = 0.02).
Subgroup analyses were performed for patients taking metoprolol versus carvedilol, for those with ST-segment elevation MI versus non–ST-segment elevation MI, patients with left ventricular ejection fraction above or below 40%, and patients who were or were not revascularized during their admission (primary percutaneous coronary intervention, later percutaneous coronary intervention, or surgery). There was a significant interaction with the effect of beta-blocker dose only for revascularization (p = 0.037). In patients undergoing revascularization, the HRs compared with the >50% dose were 0.649 (95% CI: 0.472 to 0.891), 0.546 (95% CI: 0.403 to 0.740), and 0.768 (95% CI: 0.563 to 1.048) for the >0% to 12.5%, >12.5% to 25%, and >25% to 50% doses, respectively. In nonrevascularized patients, these effects were less pronounced (HR: 1.294; 95% CI: 0.940 to 1.782; HR: 0.963; 95% CI: 0.709 to 1.308; HR: 1.223; 95% CI: 0.901 to 1.660) for the >0% to 12.5%, >12.5% to 25%, and >25% to 50% doses.
The present study was designed to evaluate whether higher dose beta-blocker therapy is associated with increased survival compared with lower doses in patients discharged from the hospital after MI. Contrary to our hypothesis, improved outcome with higher dose beta-blocker therapy (specifically the target beta-blocker doses used in previous randomized clinical trials) was not observed. Although baseline differences in the treatment groups preclude a definitive determination of the dose–response relationship between beta-blocker dose and mortality post-MI, the lowest observed mortality was at 25% of the target dose (i.e., metoprolol 50 mg/day). However, there was no consistent statistically significant reduction in mortality with this dose with the various analyses used to adjust for baseline differences among the groups. In relation to these findings, the existing evidence base from randomized clinical trials incorporated primarily target doses and provided no information regarding the dose–response of post-MI beta-blocker therapy on subsequent survival. Thus, the present registry data remain consistent with prior clinical trials that reported a benefit of full-dose beta-blocker therapy. However, they raise the question of whether lower doses may result in equivalent outcomes compared with the target dose. These data support the need for further testing to determine optimal dosing of beta-blockers after MI.
Because there are several potential explanations for the results, these intriguing findings from the registry require careful explication. First, it remains possible, although unlikely, that target dose beta-blocker therapy is still associated with better survival than lower doses; this would be possible in this registry if some unmeasured confounder(s) were unequally represented in the target and lower dose groups, making the former a substantially higher risk group than the low-dose group in which accounting for this parameter would substantially alter (reverse) the estimates of the adjusted survival. It is more feasible that further adjusting for other unmeasured confounders would show that there is no strong dose dependence of beta-blocker effect. In other words, once a threshold dose is achieved, further increments in the dose do not provide further benefit. In addition, the registry data are consistent with a greater benefit at lower doses than the target doses used in the clinical trials, but this claim would need to be tested prospectively. Finally, it is conceivable that there is no single optimal dose for all post-MI patients, with some patients benefiting from lower doses and some patients requiring higher doses. Because the trial hypothesis was that higher doses would be associated with improved outcomes, an a priori noninferiority analysis was not proposed to show noninferiority of the >12.5% to 25% target dose. Although it would not be appropriate to conduct noninferiority testing with a margin determined in a post-hoc manner, our post-hoc calculations showed that the noninferiority margin which would change the conclusion regarding noninferiority of the >12.5% to 25% target dose would have to be relatively small. Further studies will need to determine whether fixed target dosing for all post-MI patients or individualized dosing on the basis of patient or MI characteristics will optimize outcomes.
A variety of data support the biologic plausibility for the lack of a uniform improved survival with target dose versus low-dose beta-blocker therapy post-MI. Because most of the randomized clinical trial data for the beneficial effects of beta-blocker therapy were derived before thrombolysis, primary angioplasty, and routine use of aspirin, statins, and ACE inhibitors, the benefit of beta-blockers in the modern era has often been questioned. Meta-analyses including >50,000 patients from the early randomized trials of post-MI beta-blocker therapy (1,2) demonstrated 19% to 23% reductions in mortality. The more contemporary CAPRICORN (Effect of Carvedilol on Outcome After Myocardial Infarction in Patients With Left Ventricular Dysfunction) (15) randomized trial of carvedilol in post-MI patients with a left ventricular ejection fraction ≤40% also demonstrated a 23% reduction in all-cause mortality. Notably, in CAPRICORN, 74% of patients achieved the target dose and an additional 11% achieved 50% of the target dose. Large-scale observational studies (3–5) from Medicare databases documented the benefits of beta-blocker therapy in an era of rampant underuse. The largest contemporary trial, COMMIT (Clopidogrel and Metoprolol in Myocardial Infarction Trial) (20), randomized 45,852 patients with suspected acute MI to receive metoprolol (initially intravenous followed by 200 mg orally daily) versus placebo and noted no reduction in mortality at 28 days. A 2014 meta-analysis (21) comparing the effect of beta-blockers on mortality after MI in the pre- versus post-reperfusion eras noted no benefit in the post-reperfusion era. Finally, a contemporary observational report identified a 15% reduction in mortality with beta-blocker therapy after MI (22). The changes in the therapeutic landscape of MI care and the variable reported outcomes provide further rationale to re-explore the effect of beta-blocker treatment and dosing on outcomes after MI.
Several studies (8,9) have noted beta-blocker underdosing relative to clinical trial doses. There are scant data overall and no randomized clinical trial data addressing whether this represents an acceptable or “poor” clinical practice. A 1998 retrospective cohort study (23) of 1,165 post-MI patients, of whom 365 were treated with beta-blockers, is the only previous study evaluating the effect of dose on outcome. Unadjusted mortality at a mean follow-up of approximately 2 years in those treated with ≥50% and <50% of the target dose was 6.9% and 3.4%, respectively. Multivariable analysis demonstrated a 67% reduction in cardiovascular mortality associated with low-dose beta-blockers. Interestingly, a study of 208 post-MI patients (24), of whom 154 were treated with a mean beta-blocker dose of 34% of the target dose, demonstrated a 60% reduction in all-cause mortality at a mean follow-up of 58.5 months. Because no previous randomized clinical trials evaluated whether low-dose or target dose beta-blocker therapy results in improved outcomes after MI, the OBTAIN registry establishes clinical equipoise for this issue and justifies further evaluation.
Dose-dependent effects of beta-blockers in the setting of heart failure have been examined, with somewhat inconsistent results (25–27). Whereas some trials (26,27) have shown a direct relationship of dose to survival, a meta-analysis (28) found no significant difference in mortality reduction between the trials in which patients received ≥50% of the target dose versus low doses (relative risk: 0.74 and 0.78, respectively); a relationship to heart rate reduction was noted. Although there may be some commonality of purpose in the use of beta-blockers post-MI and in heart failure, it is also possible that the dose–response relationships are different, reflecting important variations in underlying global and regional autonomic abnormalities (particularly in the degree of sympathoexcitation) between the 2 conditions. Furthermore, it is possible that the dose–response relationships for the beneficial effects of beta-blockers, even among subgroups of patients with MI, may be flatter than the dose–response relationships for adverse effects, including those that might affect the conduction system or cause metabolic adverse effects (e.g., hyperlipidemia, insulin resistance) (29).
The predominant mechanisms of the benefit for beta-blocker therapy after MI are reductions in ischemia, reinfarction, and sudden death. In the era of revascularization, aspirin, and statin use, it is plausible that the contribution of beta-blocker therapy to reductions in ischemia and reinfarction are not as prominent as when the initial beta-blocker clinical trials were performed. In fact, a 41% reduction in sudden death was reported in a pooled analysis of 5 studies evaluating trials of metoprolol post-MI, accounting for virtually all the difference in total mortality between the patients receiving metoprolol and placebo (30). Although it is possible that this benefit plays an even more prominent role in the modern era of post-MI treatment, it is also interesting to note that the presenting rhythms for out-of-hospital cardiac arrest have undergone transformation over the last decades, with a decline in ventricular fibrillation and an increase in pulseless electrical activity/asystole (31). The natural history of this change is uncertain but may reflect, at least in part, the use of beta-blockers. Of particular interest is a report that noted an adjusted odds ratio of 5 for beta-blocker use among out-of-hospital cardiac arrest survivors presenting with pulseless electrical activity versus ventricular fibrillation (32). The potential importance of bradyarrhythmias was further highlighted in the CARISMA (Cardiac Arrhythmias and Risk Stratification After Acute Myocardial Infarction) study (33), in which post-MI patients with a left ventricular ejection fraction <40% received an implantable cardiac monitor. At the 2-year follow-up, 17% of patients had either high-degree atrioventricular block, significant sinus bradycardia, or sinus arrest.
Personal factors that might influence the optimal beta-blocker dose include individual risk on the basis of patient and MI characteristics, genetic polymorphisms, and observed beta-blocker effect. For example, the OACIS (Osaka Acute Coronary Insufficiency Study) registry (34) noted improved survival with beta-blocker therapy after ST-segment elevation MI only in the higher risk subgroup. Some data suggest that beta-adrenergic receptor polymorphisms influence outcomes in acute coronary syndromes and heart failure (35–38), but the dose–response effect is unknown. Furthermore, genetic polymorphisms may affect beta-blocker metabolism and concentration (39,40). A number of analyses have suggested that mortality reduction post-MI is related more to the degree of heart rate reduction than to the type of beta-blocker (10,11). Whether these factors can allow for optimal titration of beta-blocker dose for an individual post-MI patient requires further study.
There are several reasons for the current high rate of low-dose beta-blocker therapy post-MI. This may represent either physician or patient inertia. Some patients may not be able to tolerate higher doses for hemodynamic reasons or due to noncardiac adverse effects or a more severe medical condition. Finally, advanced conduction system or myocardial disease may also preclude dose up-titration. There is no a priori reason for these factors to bias toward greater benefit with lower doses.
An important caveat for the current findings is that they do not represent randomized clinical trial results. As such, multiple beta-blockers were used, and the doses were indexed to doses used in clinical trials. Although this method does not assure equivalent effects, it should be noted that 93% of the treated patients in this registry received either metoprolol or carvedilol, which was accounted for in the sensitivity analyses. In addition, the survival analysis was indexed to the discharge beta-blocker dose. Although dose changes do occur over time, only a minority of patients had their doses up-titrated. Being a registry, there was also nonuniform distribution of risk factors among groups. In addition, the specific rationale for the individual dosing regimens is unknown. Thus, the multivariable/propensity score analyses may have incompletely adjusted for these differences, and there may be unmeasured covariates, such as the extent of coronary artery disease or follow-up heart rate and blood pressure, which could affect the findings. However, multivariable adjustment and propensity score analyses consistently showed no greater benefit with full-dose beta-blocker therapy, contrary to the original hypothesis. Thus, despite these limitations, it is apparent that there is a need to stimulate further randomized trials of post-MI beta-blocker therapy from their currently dormant state.
Current practice is characterized by the use of low-dose beta-blocker therapy post-MI. To date, no data support this practice, as all the randomized clinical trials used higher target doses. Because these trials did not include dose titration studies, the present findings are not in conflict with the randomized clinical trial data. Importantly, further research is needed to establish optimal (personalized) beta-blocker dosing after MI.
COMPETENCY IN PATIENT CARE AND PROCEDURAL SKILLS: Therapy with beta-adrenergic antagonist drugs is recommended for patients after MI, but the most commonly prescribed doses are one-quarter of the dose evaluated in the randomized clinical trials that demonstrated efficacy, and optimum doses have not been validated.
TRANSLATIONAL OUTLOOK: Additional research is needed to compare various doses of beta-blockers in survivors of MI and to identify factors that influence optimum dose selection.
The authors thank Daya Alexander for her special contributions to the conduct and management of this study.
This research was supported by grant 5U01HL080416 from the National Heart, Lung, and Blood Institute of the National Institutes of Health. The views expressed in this manuscript are the authors' and do not necessarily reflect those of the National Institutes of Health or the Department of Health and Human Services. Dr. Liu is a consultant to Celladon, Outcome Research Solutions, and Zensun. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
- Abbreviations and Acronyms
- angiotensin-converting enzyme
- confidence interval
- hazard ratio
- myocardial infarction
- Received May 23, 2015.
- Revision received July 20, 2015.
- Accepted July 21, 2015.
- American College of Cardiology Foundation
- Freemantle N.,
- Cleland J.,
- Young P.,
- et al.
- O'Gara P.T.,
- Kushner F.G.,
- Ascheim D.D.,
- et al.
- Anderson J.L.,
- Adams C.D.,
- Antman E.M.,
- et al.
- Arnold S.V.,
- Spertus J.A.,
- Masoudi F.A.,
- et al.
- Cucherat M.
- The MIAMI Trial Research Group
- Viskin S.,
- Kitzis I.,
- Lev E.,
- et al.
- Chen Z.M.,
- Pan H.C.,
- Chen Y.P.,
- et al.,
- for the COMMIT (Clopidogrel and Metoprolol in Myocardial Infarction Trial) Collaborative Group
- Andersson C.,
- Shilane D.,
- Go A.S.,
- et al.
- Wikstrand J.,
- Hjalmarson A.,
- Waagstein F.,
- et al.,
- for the MERIT-HF Study Group
- Metra M.,
- Torp-Pedersen C.,
- Swedberg K.,
- et al.
- Dobre D.,
- van Veldhuisen D.J.,
- Mordenti G.,
- et al.,
- for the SENIORS Investigators
- Olsson G.,
- Wikstrand J.,
- Warnold I.,
- et al.
- Hulleman M.,
- Berdowski J.,
- de Groot J.R.,
- et al.
- Bloch Thomsen P.E.,
- Jons C.,
- Raatikainen M.J.,
- et al.,
- for the Cardiac Arrhythmias and Risk Stratification After Acute Myocardial Infarction (CARISMA) Study Group
- Nakatani D.,
- Sakata Y.,
- Suna S.,
- et al.,
- for the Osaka Acute Coronary Insufficiency Study (OACIS) Investigators
- Cresci S.,
- Dorn G.W. II.,
- Jones P.G.,
- et al.
- Aleong R.G.,
- Sauer W.H.,
- Robertson A.D.,
- et al.